24-Week Results From a PatientsLikeMe Observational Study: Vortioxetine vs Standard of Care Antidepressants in Major Depressive Disorder
Background: This study assessing patient’s real-world experience through PatientsLikeMe (PLM) online platform, aims to understand the treatment experience of patients with major depressive disorder (MDD) who have a new start/switch to vortioxetine vs other standard of care (SOC) antidepressants (ADs).
Methods: This prospective, 24-week study involved patients with MDD aged ≥18 years from the US PLM community with a recent AD start/switch. Primary endpoint was Patient Global Impression of Improvement (PGI-I) score at week 12 in patients on vortioxetine vs other SOC. Key secondary endpoints included results from 24-week PGI-I, PDQ-D5, WHO-5, Q-LES-Q-SF, and PHQ-9 scores. Here, we report the 24-week analysis results.
Results. At week 24, 454 patients completed a survey with 5.3% (n=7) of patients in the vortioxetine and 0.31% (n=1) in the other SOC group reporting improvements in PGI-I scores ( < 2). Significantly greater decrease in mean (SD) PGI-I score was observed in the vortioxetine vs other SOC at 24-weeks (2.98 [0.85] vs 3.35 [0.83]; P < 0.001) and from 12- to 24-weeks (–0.64 [1.06] vs –0.24 [1.33] points; P < 0.01). Numerically better PDQ-D5 scores (6.96 vs 7.65; P=0.19) and significantly improved mean scores for WHO-5 (54.12 vs 44.31; P < 0.001) and Q-LES-Q-SF (66.34 vs 62.35; P < 0.001) were observed in vortioxetine vs other SOC. Remission rate (PHQ-9 score < 5 at 24-week) was significantly higher in vortioxetine (n=15) vs other SOC (n=8; χ2=13.56; P < 0.001).
Conclusion: At 24-weeks, improvements in PGI-I scores, mood symptoms, well-being, life satisfaction, and cognitive functioning were observed with a new start/switch of vortioxetine vs other SOC AD treatments.
